Combining simplex and multiplexing capabilities with PentaBase’s unique DNA technologies and open platform designs, SensiScreen® assays deliver profound sensitivity and flexibility in the analysis of somatic mutations, to aid in the selection of proper cancer treatment based on the patient’s mutational status
Common cancers including colorectal cancer, lung cancer and malignant melanoma are characterized by the accumulation of somatic mutations, some of which are known to affect a patient’s response to cancer treatments. SensiScreen® qPCR-based assays provide fast and reliable somatic mutation detection to support rapid initiation of the optimal cancer treatment.
The assay is available in 2 formats:
Analysis of liquid biopsies
Analysis of FFPE biopsies
SensiScreen® liquid provides a highly effective analysis of somatic mutations done on top-of-the-line real-time PCR equipment such as the BaseTyper™ 48. The high sensitivity of SensiScreen® liquid allows the detection of down to one copy of genomic human DNA in liquid biopsies. In addition to its use as an aid in treatment selection, SensiScreen® liquid is highly suitable for monitoring a patient’s response progression and resistance to cancer therapies using liquid biopsies. Thereby, it allows for a more personalised treatment planning and adjustment. SensiScreen® liquid assay can be provided as either Ready-to-use (RTU) or Dispense-ready (DR) versions to offer optimal convenience for its users.
SensiScreen® Liquid benefits:
Result in less than three hours
Limit of detection down to one copy
Simplex or multiplex configurations.
High sensitivity and cost-effective
SensiScreen® FFPE provides an astoundingly efficient and sensitive analysis of somatic mutations found in solid biopsies. The analysis is done on top-of-the-line real-time PCR equipment such as the BaseTyper™ 48.4. This enables the assay to detect down to 0.25 per cent of mutated DNA in a wild type background in solid biopsies. SensiScreen® FFPE assay can be provided as either Ready-to-use (RTU) or Dispense-ready (DR) versions to offer optimal convenience for its users.
SensiScreen® FFPE benefits:
Result in less than three hours
Limit of detection down to point 0.25 per cent of mutated DNA
High sensitivity and cost-effective
Simplex or multiplex configurations
The SensiScreen® assay is validated to be used on BaseTyper™48 (PentaBase PCR instrument) and the following instruments:
Rotor-Gene (Qiagen)
MX3000P/3005P (Agilent)
LightCycler® 96 + 480 (Roche)
CFX96TM (Bio-Rad)
ABI 7500/7900HT (Applied Biosystems)
MIC (Bio Molecular Systems)
MyGo Pro (IT-IS Life Science)
